ICCC · Immucell Corp /De/
$11.01
-0.23 (-2.05%)
At close · Jul 29
Market Cap
$99.61M
Shares
9.05M
Immucell Corp Earnings Call Transcripts
Every quarterly earnings call for Immucell Corp (ICCC) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼6.9%
$4.80M
−$655,078
'22 Q3
22-10-05
▼28.2%
$3.91M
−$1.67M
'22 Q4
23-02-21
▼42.6%
$3.45M
−$2.32M
'23 Q1
23-04-05
▼8.5%
$3.53M
−$1.38M
'23 Q2
23-08-10
▲12.5%
$5.40M
−$940,000
'23 Q3
23-10-05
▲30.3%
$5.10M
−$1.14M
'23 Q4
24-02-27
▲110.6%
$7.26M
−$437,868
'24 Q1
24-04-09
▲54.9%
$5.47M
−$1.53M
'24 Q2
24-08-13
▲11.4%
$6.01M
−$701,690
'24 Q3
24-11-13
▲52.1%
$7.75M
$514,555
'24 Q4
25-01-10
▲11.2%
$8.07M
$1.45M
'25 Q1
25-05-14
▲17.8%
$6.44M
$501,880
'25 Q2
25-07-09
▼8.4%
$5.51M
−$139,748
'25 Q3
25-10-07
▼1.6%
$7.63M
−$2.85M
'25 Q4
26-03-04
LATEST
▲28.4%
$10.36M
$1.94M
'26 Q1
26-05-14
Earnings call
FY26 · Q2
2026-07-09
Immucell Corp /De/ Q2 FY2026 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Immucell Corp /De/ Q1 FY2026 Earnings Call
Confident tone
Revenue growth and First Quarter milestone
Strategic focus on First Defense / Tri-Shield
Manufacturing yield and capacity expansion
Revenue
$10.36M
▲ 28.4% YoY Diluted EPS
$0.21
▲ 31.2% YoY Gross margin
45.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Immucell Corp /De/ Q4 FY2025 Earnings Call
Confident tone
First Defense franchise focus and strategy shift
Re-Tain write-down and exit
Gross margin improvement
Revenue
$7.63M*
▼ 1.6% YoY Gross margin
38.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-07
Immucell Corp /De/ Q3 FY2025 Earnings Call
Confident tone
Revenue and sales performance
Financial turnaround and profitability
First Defense product growth
Revenue
$5.51M
▼ 8.4% YoY Diluted EPS
$-0.02
Gross margin
42.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-09
Immucell Corp /De/ Q2 FY2025 Earnings Call
Positive tone
First Defense production capacity and recovery
Re-Tain development and FDA pathway
Colostrum inventory management
Revenue
$6.44M
▲ 17.8% YoY Diluted EPS
$0.06
Gross margin
43.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Immucell Corp /De/ Q1 FY2025 Earnings Call
Confident tone
First Defense sales growth and product suite
Re-Tain investigational product use and FDA approval
Gross margin improvement
Revenue
$8.07M
▲ 11.2% YoY Diluted EPS
$0.16
Gross margin
41.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Immucell Corp /De/ Q4 FY2024 Earnings Call
Confident tone
Gross margin improvement
Re-Tain FDA approval and commercial launch
Contamination remediation and production yields
Revenue
$7.75M*
▲ 52.1% YoY Gross margin
36.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Immucell Corp /De/ Q3 FY2024 Earnings Call
Revenue
$6.01M
▲ 11.4% YoY Diluted EPS
$-0.09
Gross margin
26.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Immucell Corp /De/ Q2 FY2024 Earnings Call
Positive tone
Re-Tain FDA regulatory process
Contamination events and remediation
Gross margin pressure
Revenue
$5.47M
▲ 54.9% YoY Diluted EPS
$-0.20
Gross margin
22.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-09
Immucell Corp /De/ Q1 FY2024 Earnings Call
Positive tone
Gross Margin Improvement to Target
Retain Regulatory Delays
Record Sales Growth and Production Output
Revenue
$7.26M
▲ 110.6% YoY Diluted EPS
$-0.06
Gross margin
31.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Immucell Corp /De/ Q4 FY2023 Earnings Call
Balanced tone
Re-Tain FDA submission and approval timeline
Contamination events and remediation
Backlog and demand
Revenue
$5.10M*
▲ 30.3% YoY Gross margin
24.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-05
Immucell Corp /De/ Q3 FY2023 Earnings Call
Revenue
$5.40M
▲ 12.5% YoY Diluted EPS
$-0.12
Gross margin
23.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Immucell Corp /De/ Q2 FY2023 Earnings Call
Revenue
$3.53M
▼ 8.5% YoY Diluted EPS
$-0.18
Gross margin
29.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-05
Immucell Corp /De/ Q1 FY2023 Earnings Call
Revenue
$3.45M
▼ 42.6% YoY Diluted EPS
$-0.30
▼ 528.6% YoY Gross margin
8.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
Immucell Corp /De/ Q4 FY2022 Earnings Call
Revenue
$3.91M*
▼ 28.2% YoY Gross margin
25.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-05
Immucell Corp /De/ Q3 FY2022 Earnings Call
Revenue
$4.80M
▼ 6.9% YoY Diluted EPS
$-0.08
▼ 500% YoY Gross margin
38.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-07
Immucell Corp /De/ Q2 FY2022 Earnings Call
Revenue
$3.86M
▼ 15% YoY Diluted EPS
$-0.09
▼ 550% YoY Gross margin
44.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Immucell Corp /De/ Q1 FY2022 Earnings Call
Revenue
$6.00M
▲ 46.1% YoY Diluted EPS
$0.07
Gross margin
51.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Immucell Corp /De/ Q4 FY2021 Earnings Call
Revenue
$5.44M*
▲ 45.4% YoY Gross margin
47.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-06
Immucell Corp /De/ Q3 FY2021 Earnings Call
Revenue
$5.15M
▲ 38.4% YoY Diluted EPS
$0.02
Gross margin
47.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Immucell Corp /De/ Q2 FY2021 Earnings Call
Revenue
$4.54M
▲ 53.1% YoY Diluted EPS
$0.02
Gross margin
45.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Immucell Corp /De/ Q1 FY2021 Earnings Call
Revenue
$4.11M
▼ 16.4% YoY Diluted EPS
$-0.06
Gross margin
39.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Immucell Corp /De/ Q4 FY2020 Earnings Call
Revenue
$3.74M*
▲ 3.1% YoY Gross margin
43.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Immucell Corp /De/ Q3 FY2020 Earnings Call
Revenue
$3.72M
▲ 25.3% YoY Diluted EPS
$-0.04
Gross margin
46.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-07
Immucell Corp /De/ Q2 FY2020 Earnings Call
Revenue
$2.97M
▲ 9.4% YoY Diluted EPS
$-0.11
Gross margin
43.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-13
Immucell Corp /De/ Q1 FY2020 Earnings Call
Revenue
$4.91M
▲ 11.3% YoY Diluted EPS
$-0.02
▼ 166.7% YoY Gross margin
45.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-18
Immucell Corp /De/ Q4 FY2019 Earnings Call
Revenue
$3.63M*
▲ 23.7% YoY Gross margin
50.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls